JP2015506348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506348A5 JP2015506348A5 JP2014548913A JP2014548913A JP2015506348A5 JP 2015506348 A5 JP2015506348 A5 JP 2015506348A5 JP 2014548913 A JP2014548913 A JP 2014548913A JP 2014548913 A JP2014548913 A JP 2014548913A JP 2015506348 A5 JP2015506348 A5 JP 2015506348A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nhr
- aryl
- salt
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 36
- -1 1,2,3,4-tetrahydronaphthyl Chemical group 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 150000002148 esters Chemical class 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 16
- 230000009385 viral infection Effects 0.000 claims description 16
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 241000711902 Pneumovirus Species 0.000 claims description 10
- 150000001721 carbon Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 8
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 108700002314 gontivimab Proteins 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 229960001521 motavizumab Drugs 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 229960000402 palivizumab Drugs 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 5
- 229960000329 ribavirin Drugs 0.000 claims description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 5
- 125000006736 (C6-C20) aryl group Chemical group 0.000 claims description 4
- BLUJRJMLDHEMRX-UHFFFAOYSA-N 2-[[2-hydroxy-5-[(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1N=Cc1ccc(O)c(c1)C(c1ccc(O)cc1)c1cc(C=Nn2nnnc2C)ccc1O BLUJRJMLDHEMRX-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000005493 quinolyl group Chemical group 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 claims description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- KSHJXDWYTZJUEI-UHFFFAOYSA-N 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one Chemical compound N=1C2=CC=CC=C2N(CCCCO)C=1CN(C1=O)C2=CN=CC=C2N1C1CC1 KSHJXDWYTZJUEI-UHFFFAOYSA-N 0.000 claims 1
- 241000711904 Pneumoviridae Species 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 Cc1c[n]2nc(C(CCCC3)N3C(c3c(C(F)(F)F)cccc3)=O)cc2nc1N(C[C@]1*)C[C@@]1O Chemical compound Cc1c[n]2nc(C(CCCC3)N3C(c3c(C(F)(F)F)cccc3)=O)cc2nc1N(C[C@]1*)C[C@@]1O 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- LJMJHHZSIVNEMW-UXPWSPDFSA-N CC(C)[n]1ncc(Cl)c1C(N(CCCC1)[C@@H]1c1n[n](cc(C)c(N(C[C@H]2C#N)C[C@@H]2O)n2)c2c1)=O Chemical compound CC(C)[n]1ncc(Cl)c1C(N(CCCC1)[C@@H]1c1n[n](cc(C)c(N(C[C@H]2C#N)C[C@@H]2O)n2)c2c1)=O LJMJHHZSIVNEMW-UXPWSPDFSA-N 0.000 description 2
- OKQLFHTVGNRMND-HOJAQTOUSA-N Cc1c(C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)nccc1 Chemical compound Cc1c(C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)nccc1 OKQLFHTVGNRMND-HOJAQTOUSA-N 0.000 description 2
- VZMDKBIHWMCMLN-BUJZBAMKSA-N Cc1c[n]2nc(C(CCCC3)N3C(c(cc(cc3)F)c3Cl)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc(C(CCCC3)N3C(c(cc(cc3)F)c3Cl)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O VZMDKBIHWMCMLN-BUJZBAMKSA-N 0.000 description 2
- IPAMMMZKTPRJIG-ICTDUYRTSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c(cccc3)c3-c3ccccc3)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c(cccc3)c3-c3ccccc3)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O IPAMMMZKTPRJIG-ICTDUYRTSA-N 0.000 description 2
- RRNSJMLVNQMNPL-WTNAPCKOSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3c[s]c4c3CCCC4)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3c[s]c4c3CCCC4)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O RRNSJMLVNQMNPL-WTNAPCKOSA-N 0.000 description 2
- ZGUFLPWZJOKDCS-NEWSRXKRSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3c[s]cc3)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3c[s]cc3)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O ZGUFLPWZJOKDCS-NEWSRXKRSA-N 0.000 description 2
- VZKFSGYKBYXYOF-XGRCMKMKSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3cc(OC)ccc3Cl)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3cc(OC)ccc3Cl)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O VZKFSGYKBYXYOF-XGRCMKMKSA-N 0.000 description 2
- HYZRHOCPKOUTIS-OIBXWCBGSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3cccc4c3cc[n]4C)=O)cc2nc1N(C[C@H]1N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3cccc4c3cc[n]4C)=O)cc2nc1N(C[C@H]1N)C[C@@H]1O HYZRHOCPKOUTIS-OIBXWCBGSA-N 0.000 description 2
- TUKONYDEGAMPCN-AYBZRNKSSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3ccn[n]3CC(F)(F)F)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3ccn[n]3CC(F)(F)F)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O TUKONYDEGAMPCN-AYBZRNKSSA-N 0.000 description 2
- WNLZNPSVISTKRX-NJAFHUGGSA-N Cc1n[n](C)c(C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)c1Cl Chemical compound Cc1n[n](C)c(C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)c1Cl WNLZNPSVISTKRX-NJAFHUGGSA-N 0.000 description 2
- BBWFJUUKVGEWCJ-UHBFCERESA-N CC(C(CCCC1)N1C(c1cc(CCC=C2)c2cc1OC)=O)/C=C(/C(CC(C(C)=C1)N(CC2)CC2N)=C)\N1N Chemical compound CC(C(CCCC1)N1C(c1cc(CCC=C2)c2cc1OC)=O)/C=C(/C(CC(C(C)=C1)N(CC2)CC2N)=C)\N1N BBWFJUUKVGEWCJ-UHBFCERESA-N 0.000 description 1
- NZVMRLZBENHKIT-UHFFFAOYSA-N CC1=CN2NC(C(CCCC3)N3C(c3cc(Cl)cc(Cl)n3)O)C=C2N=C1N(CC1)CC1N Chemical compound CC1=CN2NC(C(CCCC3)N3C(c3cc(Cl)cc(Cl)n3)O)C=C2N=C1N(CC1)CC1N NZVMRLZBENHKIT-UHFFFAOYSA-N 0.000 description 1
- ZUHIBVFHQMDMSE-CQLNOVPUSA-N C[C@H](CN(C1)c2nc3cc([C@H](CCCC4)N4C(c(cc(CCC4)c4c4)c4OC)=O)n[n]3cc2C)[C@H]1O Chemical compound C[C@H](CN(C1)c2nc3cc([C@H](CCCC4)N4C(c(cc(CCC4)c4c4)c4OC)=O)n[n]3cc2C)[C@H]1O ZUHIBVFHQMDMSE-CQLNOVPUSA-N 0.000 description 1
- DQXXQOYYRHQWOT-PBXQCXKZSA-N C[C@H](CN(C1)c2nc3cc([C@H](CCCC4)N4C(c4nccc(-c5ccccc5)c4)=O)n[n]3cc2C)[C@H]1O Chemical compound C[C@H](CN(C1)c2nc3cc([C@H](CCCC4)N4C(c4nccc(-c5ccccc5)c4)=O)n[n]3cc2C)[C@H]1O DQXXQOYYRHQWOT-PBXQCXKZSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BDCMMTOBVDRGBX-UXPWSPDFSA-N Cc(ccc(F)c1C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)c1F Chemical compound Cc(ccc(F)c1C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)c1F BDCMMTOBVDRGBX-UXPWSPDFSA-N 0.000 description 1
- SFAZXGULNIOTOJ-PUHATCMVSA-N Cc1c(C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)[nH]c2c(C)ccc(C)c12 Chemical compound Cc1c(C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)[nH]c2c(C)ccc(C)c12 SFAZXGULNIOTOJ-PUHATCMVSA-N 0.000 description 1
- DZCASUFRISLUAW-UHFFFAOYSA-N Cc1c[n]2nc(C(CCCC3)N3C(C3=CCCC4=C3CNN4C)O)cc2nc1N(CC1)CC1NC Chemical compound Cc1c[n]2nc(C(CCCC3)N3C(C3=CCCC4=C3CNN4C)O)cc2nc1N(CC1)CC1NC DZCASUFRISLUAW-UHFFFAOYSA-N 0.000 description 1
- GEXFZAQAQKDOFK-UHFFFAOYSA-N Cc1c[n]2nc(C(CCCC3)N3C(c(cc3)ncc3Cl)=O)cc2nc1N(CC1)CC1NC Chemical compound Cc1c[n]2nc(C(CCCC3)N3C(c(cc3)ncc3Cl)=O)cc2nc1N(CC1)CC1NC GEXFZAQAQKDOFK-UHFFFAOYSA-N 0.000 description 1
- GXUXOOMUDORFPZ-UHFFFAOYSA-N Cc1c[n]2nc(C(CCCC3)N3C(c3c[s]c(cc4)c3cc4Br)O)cc2nc1N(CC1)CC1N Chemical compound Cc1c[n]2nc(C(CCCC3)N3C(c3c[s]c(cc4)c3cc4Br)O)cc2nc1N(CC1)CC1N GXUXOOMUDORFPZ-UHFFFAOYSA-N 0.000 description 1
- UMEMAYVFWWNFBR-QLEIAVNASA-N Cc1c[n]2nc([C@H](CCCC3)N3C(C3C=CC4=CC=CCC4C3)=O)cc2nc1N(CC1)CC1N Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(C3C=CC4=CC=CCC4C3)=O)cc2nc1N(CC1)CC1N UMEMAYVFWWNFBR-QLEIAVNASA-N 0.000 description 1
- CVXOOYSXUGCKIK-XGRCMKMKSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c(c(F)c3)ccc3OC)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c(c(F)c3)ccc3OC)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O CVXOOYSXUGCKIK-XGRCMKMKSA-N 0.000 description 1
- OJLTTZSVHLCMAL-RZFJZAQRSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c(cc3)ncc3-c3ccccc3)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c(cc3)ncc3-c3ccccc3)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O OJLTTZSVHLCMAL-RZFJZAQRSA-N 0.000 description 1
- LTLAPWAEPHATSO-LEOXJPRUSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c(ccc3ccc4)nc3c4F)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c(ccc3ccc4)nc3c4F)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O LTLAPWAEPHATSO-LEOXJPRUSA-N 0.000 description 1
- LWQANBKGJRSQOD-XGRCMKMKSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3cc(Cl)ccc3NS(C)(=O)=O)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3cc(Cl)ccc3NS(C)(=O)=O)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O LWQANBKGJRSQOD-XGRCMKMKSA-N 0.000 description 1
- RCEBYRIHHSYWMN-WTNAPCKOSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3cc(F)cc4c3OCOC4)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3cc(F)cc4c3OCOC4)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O RCEBYRIHHSYWMN-WTNAPCKOSA-N 0.000 description 1
- MRXWDPJDCLGSHP-AGHHOFFYSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3cccc4ccn[n]34)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3cccc4ccn[n]34)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O MRXWDPJDCLGSHP-AGHHOFFYSA-N 0.000 description 1
- FSHGZALLVVXDGZ-LEOXJPRUSA-N Cc1c[n]2nc([C@H](CCCC3)N3C(c3nc4ccncc4cc3)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O Chemical compound Cc1c[n]2nc([C@H](CCCC3)N3C(c3nc4ccncc4cc3)=O)cc2nc1N(C[C@H]1C#N)C[C@@H]1O FSHGZALLVVXDGZ-LEOXJPRUSA-N 0.000 description 1
- DZMBFEFYCVIZBP-UHFFFAOYSA-N Cc1ccc(C(N(CCCC2)C2c2n[n](cc(C)c(N3CCCC3)n3)c3c2)O)c(OC)c1 Chemical compound Cc1ccc(C(N(CCCC2)C2c2n[n](cc(C)c(N3CCCC3)n3)c3c2)O)c(OC)c1 DZMBFEFYCVIZBP-UHFFFAOYSA-N 0.000 description 1
- MGKPNWCWSKJHES-WTNAPCKOSA-N Cc1ccc(C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)c(Cl)c1 Chemical compound Cc1ccc(C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C[C@@H]3O)n3)c3c2)=O)c(Cl)c1 MGKPNWCWSKJHES-WTNAPCKOSA-N 0.000 description 1
- NXXYUNPTIPXYSD-GCJKJVERSA-N Cc1n[o]c(-c(cccc2)c2C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C=C3O)n3)c3c2)=O)n1 Chemical compound Cc1n[o]c(-c(cccc2)c2C(N(CCCC2)[C@@H]2c2n[n](cc(C)c(N(C[C@H]3C#N)C=C3O)n3)c3c2)=O)n1 NXXYUNPTIPXYSD-GCJKJVERSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579625P | 2011-12-22 | 2011-12-22 | |
| US61/579,625 | 2011-12-22 | ||
| US201261618510P | 2012-03-30 | 2012-03-30 | |
| US61/618,510 | 2012-03-30 | ||
| PCT/US2012/071065 WO2013096681A1 (en) | 2011-12-22 | 2012-12-20 | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016224719A Division JP2017036336A (ja) | 2011-12-22 | 2016-11-18 | 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506348A JP2015506348A (ja) | 2015-03-02 |
| JP2015506348A5 true JP2015506348A5 (enExample) | 2016-02-12 |
| JP6122868B2 JP6122868B2 (ja) | 2017-04-26 |
Family
ID=47557523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548913A Active JP6122868B2 (ja) | 2011-12-22 | 2012-12-20 | 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン |
| JP2016224719A Withdrawn JP2017036336A (ja) | 2011-12-22 | 2016-11-18 | 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016224719A Withdrawn JP2017036336A (ja) | 2011-12-22 | 2016-11-18 | 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8946238B2 (enExample) |
| EP (1) | EP2794611B1 (enExample) |
| JP (2) | JP6122868B2 (enExample) |
| AU (1) | AU2012358805B2 (enExample) |
| CA (1) | CA2858096C (enExample) |
| ES (1) | ES2647486T3 (enExample) |
| PT (1) | PT2794611T (enExample) |
| WO (1) | WO2013096681A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486938B2 (en) | 2010-06-24 | 2013-07-16 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines for antiviral treatment |
| PT2794611T (pt) | 2011-12-22 | 2017-12-06 | Gilead Sciences Inc | Pirazolo[1,5-a]pirimidinas como agentes antivirais |
| JP2015516976A (ja) | 2012-04-17 | 2015-06-18 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス処置のための化合物および方法 |
| BR112016003348B1 (pt) | 2013-08-21 | 2023-03-07 | Alios Biopharma, Inc | Compostos antivirais ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e seus usos |
| AU2015301334A1 (en) * | 2014-08-05 | 2017-02-23 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| SG11201704508WA (en) | 2014-12-08 | 2017-06-29 | Janssen Sciences Ireland Uc | Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv) |
| CA2963051C (en) | 2014-12-08 | 2023-10-17 | Janssen Sciences Ireland Uc | Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv) |
| SMT202100592T1 (it) | 2014-12-26 | 2021-11-12 | Univ Emory | Derivati antivirali della n4-idrossicitidina |
| MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| JP2018076234A (ja) * | 2015-03-16 | 2018-05-17 | 大正製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| RU2738232C2 (ru) | 2015-07-22 | 2020-12-09 | Энанта Фармасьютикалс, Инк. | Производные бензодиазепина как ингибиторы rsv |
| EP3402799B1 (en) | 2016-01-15 | 2022-05-04 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109153682B (zh) * | 2016-05-20 | 2021-05-25 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物 |
| CA3176428A1 (en) | 2016-10-06 | 2018-04-12 | Orbus Therapeutics, Inc. | Formulations for administration of eflornithine |
| MX379326B (es) | 2017-02-16 | 2025-03-11 | Enanta Pharm Inc | Procesos para la preparación de derivados de benzodiazepina |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| IL273428B2 (en) | 2017-09-22 | 2023-09-01 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| AU2018339068B2 (en) | 2017-09-29 | 2022-12-15 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as RSV inhibitors |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| CA3080677A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| CN111343990B (zh) | 2017-11-13 | 2023-08-04 | 英安塔制药有限公司 | 苯并二氮杂䓬-2-酮和苯并氮杂䓬-2-酮衍生物的拆分方法 |
| SMT202400203T1 (it) | 2017-11-24 | 2024-07-09 | Jubilant Episcribe Llc | Composti eterociclici come inibitori di prmt5 |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| SG11202006141RA (en) | 2018-01-31 | 2020-07-29 | Janssen Sciences Ireland Unlimited Co | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv |
| MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
| MA52348A (fr) | 2018-04-23 | 2021-03-03 | Janssen Sciences Ireland Unlimited Co | Composés hétéroaromatiques ayant une activité contre vrs |
| AU2019389616A1 (en) * | 2018-11-26 | 2021-04-29 | Janssen Sciences Ireland Unlimited Company | Further heteroaromatic compounds having activity against RSV |
| US20230069963A1 (en) | 2018-12-27 | 2023-03-09 | Taisho Pharmaceutical Co., Ltd. | Pyrazolo[1,5-a]pyrimidine macrocyclic compound |
| PH12021552201A1 (en) | 2019-03-18 | 2022-05-30 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| TWI864048B (zh) | 2019-10-04 | 2024-12-01 | 美商安塔製藥公司 | 抗病毒雜環化合物、其醫藥組成物及其用途 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| JP2024507561A (ja) | 2021-02-26 | 2024-02-20 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス複素環式化合物 |
| WO2022270628A1 (ja) * | 2021-06-25 | 2022-12-29 | 国立大学法人 大分大学 | Ｒｓウイルス感染症の処置および／または予防用医薬としてのヘテロシクロアルキル置換ポリヘテロアゾール誘導体 |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
| CN115710200B (zh) * | 2022-11-21 | 2024-08-09 | 重庆医科大学 | 苯甲酰氟类化合物、苯甲酸类化合物及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6342501B1 (en) | 1994-02-25 | 2002-01-29 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d] pyrimidines as antiviral agents |
| US5543413A (en) * | 1994-02-25 | 1996-08-06 | Regents Of The University Of Michigan | Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action |
| PL318199A1 (en) | 1994-06-29 | 1997-05-26 | Smithkline Beecham Corp | Antagonists of vitronectin receptors |
| ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
| TWI225488B (en) | 1999-12-21 | 2004-12-21 | Janssen Pharmaceutica Nv | Derivatives of homopiperidinyl substituted benzimidazole analogues |
| CA2478715A1 (en) | 2002-03-13 | 2003-09-25 | Pharmacia & Upjohn Company | Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators |
| JP2005529919A (ja) * | 2002-05-10 | 2005-10-06 | スミスクライン ビーチャム コーポレーション | 治療用化合物 |
| MXPA04012245A (es) * | 2002-06-04 | 2005-09-30 | Neogenesis Pharmaceuticals Inc | Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales. |
| DE10247271A1 (de) | 2002-10-10 | 2004-08-26 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yle |
| DE602004031258D1 (de) | 2003-12-24 | 2011-03-10 | Biota Scient Management | Polycyclische mittel zur behandlung von infektione |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| US20100055071A1 (en) | 2006-11-21 | 2010-03-04 | Martin Robert Leivers | Anti-Viral Compounds |
| NZ585784A (en) | 2007-12-13 | 2012-09-28 | Alnylam Pharmaceuticals Inc | siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection |
| WO2009079011A1 (en) | 2007-12-19 | 2009-06-25 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| EP2257552A1 (en) | 2008-02-26 | 2010-12-08 | Novartis AG | Heterocyclic compounds as inhibitors of cxcr2 |
| JP5432982B2 (ja) * | 2008-03-31 | 2014-03-05 | 武田薬品工業株式会社 | アポトーシスシグナル調節キナーゼ１阻害剤 |
| CA2721060A1 (en) | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010033701A2 (en) | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
| EP2182081B1 (de) | 2008-10-29 | 2014-01-22 | Neue Materialien Bayreuth GmbH | Verfahren zur thermischen Behandlung eines beschichteten Stahlblechkörpers |
| EA024853B1 (ru) | 2008-12-03 | 2016-10-31 | Пресидио Фармасьютикалс, Инк. | Ингибиторы ns5a вгс |
| US8609696B2 (en) | 2008-12-18 | 2013-12-17 | Boehringer Ingelheim International Gmbh | Serotonin 5-HT2B receptor inhibitors |
| US8541424B2 (en) | 2008-12-23 | 2013-09-24 | Abbott Laboratories | Anti-viral compounds |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| CN102427731B (zh) | 2009-02-27 | 2015-05-13 | 英安塔制药有限公司 | 丙型肝炎病毒抑制剂 |
| US8889674B2 (en) | 2009-03-05 | 2014-11-18 | Shionogi & Co., Ltd. | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism |
| ES2414934T3 (es) | 2009-06-11 | 2013-07-23 | Abbvie Bahamas Limited | Inhibidores del virus de la Hepatitis C |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8623899B2 (en) | 2009-08-07 | 2014-01-07 | Janssen Research & Development Ireland | Bis-benzimidazole derivatives as hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| ES2475970T3 (es) * | 2009-12-23 | 2014-07-11 | Katholieke Universiteit Leuven | Novedosos compuestos antivirales |
| WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
| CA2800509A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8486938B2 (en) | 2010-06-24 | 2013-07-16 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines for antiviral treatment |
| EP2595980B1 (en) | 2010-07-22 | 2014-09-03 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| PT2794611T (pt) | 2011-12-22 | 2017-12-06 | Gilead Sciences Inc | Pirazolo[1,5-a]pirimidinas como agentes antivirais |
| JP2015516976A (ja) | 2012-04-17 | 2015-06-18 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス処置のための化合物および方法 |
-
2012
- 2012-12-20 PT PT128140928T patent/PT2794611T/pt unknown
- 2012-12-20 JP JP2014548913A patent/JP6122868B2/ja active Active
- 2012-12-20 EP EP12814092.8A patent/EP2794611B1/en active Active
- 2012-12-20 ES ES12814092.8T patent/ES2647486T3/es active Active
- 2012-12-20 US US13/722,962 patent/US8946238B2/en active Active
- 2012-12-20 AU AU2012358805A patent/AU2012358805B2/en active Active
- 2012-12-20 WO PCT/US2012/071065 patent/WO2013096681A1/en not_active Ceased
- 2012-12-20 CA CA2858096A patent/CA2858096C/en active Active
-
2014
- 2014-12-10 US US14/566,340 patent/US9278975B2/en active Active
-
2016
- 2016-01-19 US US15/000,821 patent/US20160235748A1/en not_active Abandoned
- 2016-11-18 JP JP2016224719A patent/JP2017036336A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506348A5 (enExample) | ||
| KR101756050B1 (ko) | 톨 유사 수용체 조정제 화합물 | |
| JP2013512903A5 (enExample) | ||
| AU2013345107B2 (en) | Heteroaromatic compounds as PI3 kinase modulators and methods of use | |
| KR20190040338A (ko) | 톨 유사 수용체 조정제 화합물 | |
| JP2013542261A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2019537570A5 (enExample) | ||
| JP2011529918A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| CA2870024A1 (en) | Compounds and methods for antiviral treatment | |
| JP2014500295A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| RU2016141569A (ru) | Комбинации | |
| JP2014532716A5 (enExample) | ||
| JP2011516428A5 (enExample) | ||
| JP2010513523A5 (enExample) | ||
| JP2013529196A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2011507881A5 (enExample) | ||
| JP2019511542A (ja) | カプシド集合阻害剤を含む組み合わせ及び方法 | |
| JP2019505529A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| JP2008517913A5 (enExample) |